

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

### **VOLUNTARY ANNOUNCEMENT INTENTION OF THE CHAIRMAN AND THE SENIOR MANAGEMENT TO INCREASE SHAREHOLDING IN THE COMPANY**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was informed by Dr. Yi Zhang (“**Dr. Zhang**”) (the chairman of the Board and an executive Director) and the Company’s senior management (the “**Senior Management**”) of their intention to acquire the shares of the Company (the “**Shares**”) from the open market (the “**Proposed Shareholding Increase**”) within about one week from the date of this announcement, subject to compliance with the applicable laws and regulations. According to Dr. Zhang and the Senior Management, it is expected that the aggregate amount of consideration for the Proposed Shareholding Increase would not exceed HK\$10 million.

In addition, Dr. Zhang and the Senior Management indicated that the Shares proposed to be acquired would be held for medium- to long-term investment purposes, and they had no present intention to sell such Shares during the twelve months after the acquisition. The Board considers that the Proposed Shareholding Increase demonstrates Dr. Zhang and the Senior Management’s confidence towards the prospect and growth potential of the Company.

According to the information available to the Company and so far as the Directors are aware, the Proposed Shareholding Increase would not give rise to an obligation to make a mandatory offer under Rule 26 of the Codes on Takeovers and Mergers and Share Buybacks, and there would be sufficient public float of the Shares in issue upon completion of the Proposed Shareholding Increase.

**Shareholders of the Company and the potential investors should note that as at the date of this announcement, Dr. Zhang and the Senior Management have not proceeded with the Proposed Shareholding Increase. The Proposed Shareholding Increase will be subject to the market conditions and will be at the absolute discretion of Dr. Zhang and the Senior Management. Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, December 2, 2021

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.*